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Abstract
Patients with Hereditary Hemorrhagic Telangiectasia (HHT) frequently present with epistaxis. Up to 98 % of these
patients will have epistaxis at some point in their life. There are multiple ways to deal with this problem, including
conservative, medical and surgical options. We present a case and an update on the treatment options for HHT,
with a focus on the newer and experimental techniques.
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Case
A 37 year old male presented with recurrent epistaxis as
well as multiple telangiectasias of his fingers and anter-
ior tongue. He was previously diagnosed with Hereditary
Hemorrhagic Telangiectasia (HHT) at an outside institu-
tion. An MRI of his head was completed which did not
demonstrate any evidence of an intracranial arteriovas-
cular malformation (AVM). Bubble cardiography, used
to detect AVMs in the lungs, was also read as negative.
As the finger lesions were most bothersome to the pa-
tient, the risks of benefits of treating them with a YAG
laser were discussed and the patient elected to proceed.
Although the patient initially had a good result, he ex-
perienced recurrence of his digital telangiectasias ap-
proximately 1 year later, and he started to become more
symptomatic from his nasal lesions. Treatment with
YAG laser was again undertaken, with good result. As a
result of his frequent episodes of epistaxis, the patient
eventually developed iron-deficiency anemia, which was
treated with iron infusions (as the patient was unable to
tolerate oral iron supplementation). He required treat-
ment with YAG laser for the telangiectasias on average
every 2 years, with his anemia being maintained with
iron infusions. His epistaxis was frequent, but remained
controllable with pressure.
Unfortunately, he recently presented to the emergency
room with shortness of breath and his hemoglobin was
found to be 87. He also reported melena stools. Follow-
ing transfusion and stabilization he was re-assessed in
our outpatient Otolaryngology- Head & Neck Surgery
clinic where management with septodermoplasty was
entertained to address the epistaxis. Alternative therap-
ies, such as coblation and Bevacizumab (Avastin) are
also being considered. The patient is currently weighing
the risks and benefits of these treatment options.
Introduction
Hereditary Hemorrhagic Telangiectasia, also known as
Osler-Weber-Rendu (OWR) syndrome, was described
nearly 120 years ago [1]. In 1896 Rendu described a syn-
drome of recurrent epistaxis and telangiectasias that was
distinct from hemophilia [2]; this was followed by re-
ports from Osler [3] (in 1901) and Weber [4] (in 1907).
It is the constellation of recurrent epistaxis, familial
inheritance, AVMs and mucocutaneous telangiectasias
that now bears their names. The prevalence of HHT is
approximately 1 in 5000, but there is large geographic
variability [5]. The highest report rates are in Afro-
Caribbean residents of the Netherlands Antilles, with an
incidence of approximately 1 in 1331 [6].
HHT is diagnosed with the Curacao criteria (Fig. 1)
[7]. Histologically, the venules are dilated and lack
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contractile elastic fibers, predisposing them to bleeding
[1]. HHT is inherited in an autosomal dominant manner
with incomplete penetrance [8, 9]. This is most often
due to a defect in the ENG and ACVRL1 genes, but can
be due to other genes as well, such as SMAD4 [8]. The
telangiectasias that are seen are mucocutaneous in na-
ture and have a very characteristic appearance (Fig. 2).
They often appear on the lips, tongue, fingers, as well as
the nasal and gastric mucosa and frequently present with
bleeding (Fig. 3).
While epistaxis is the most commonly encountered
symptom for Otolaryngologists, there are many other
manifestations such as arterio-venous malformations
(AVMs) of the lungs and gastrointestinal (GI) tract. As
such, these patients are best managed in a multi-
disciplinary setting [6]. International guidelines were
created in 2011 that summarize the workup and man-
agement of the various manifestations of HHT [8]. In
summary, treatment should be considered for asymp-
tomatic cerebral and pulmonary AVMs because of their
potential catastrophic and life-threatening presentations.
When patients are symptomatic with GI, liver or oral
cavity bleeding, treatment should also be considered.
Close follow-up is required for all these patients.
Epistaxis is the most common symptom reported in
these patients and affects up to 98 % [6, 9, 10]. Approxi-
mately 50 % will have epistaxis by the age of 20 [9]. As
such, Otolaryngologist - Head and Neck Surgeons are
frequently involved in the management of these patients.
These episodes can range from minimally bothersome to
life-threatening. The Epistaxis Severity Score is a vali-
dated and useful outcome measure that was designed
specifically for HHT and can be easily used to gauge dis-
ease severity and the effect of treatment [11].
There are various different treatment options available
for epistaxis in HHT, with many new advances and inno-
vations being developed in the past few years. In the
acute setting, nasal packing with absorbable material,
manual pressure, and fluid resuscitation remain the
mainstays of therapy. This article will focus mostly on
the new surgical advances in the long-term management
of this challenging disease.
Methods
A literature review of articles and abstracts on PubMed
was completed. Search terms includes “HHT” and
“Osler-Weber-Rendu”, as well as “HHT epistaxis” and
“Osler-Weber-Rendu epistaxis”. Abstracts were then
reviewed, and those abstracts that focused on the man-
agement and treatment of HHT were selected for
inclusion.
In total, 37 articles were reviewed and summaries of
the evidence were generated based on these articles.
Two reviewers (CJC, BWR) reviewed the articles separ-
ately to ensure concordance.
Conservative therapy
There is a paucity of evidence regarding conservative
therapy for epistaxis in HHT, and epistaxis in general.
Anecdotally, it is said that patients should keep the nose
well hydrated through the use of saline rinses and with
humidification [8]. Barrier creams and topical emollients
are also routinely used [12]. In the case of HHT, the
patient must be instructed to be particularly careful
when applying the treatment (barrier or saline irriga-
tions) as the telangiectasias are extremely fragile and
have a tendency to bleed when manipulated (Additional
file 1: Video 1).
Recently, the group at Johns Hopkins has investigated
the application of Sesame/Rose Geranium oil (RGO) for
control of epistaxis in HHT. In a 2013 study, they found
a significant improvement in the Epistaxis Severity Score
in patients using RGO. The authors theorize that the
benefit from application of RGO is nasal hydration and
formation of a durable protective layer, but note is made
that further investigation is required to delineate the
mechanism of action [13].
Fig. 1 The Curaçao criteria [7]. Number of features 0–1 : unlikely, 2:
possible or suspected, 3–4: definite
Fig. 2 Endoscopic appearance of a telangiectasia on the head of
the inferior turbinate
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Lastly, for those patients who don’t mind the aesthet-
ics, nasal obturators are an option for HHT [14]. Based
on the principle that the epistaxis is often triggered by
turbulent airflow in the nasal cavity that disrupts the
telangiectasias, the obturator attempts to mimic the
Young’s procedure (discussed later in this article) by
completely occluding the nasal cavity. There is limited,
but promising, evidence for these devices in HHT [14].
Summary: Conservative therapies have a low risk
profile. Although the evidence is lacking for these
therapies, they can be considered as a non-invasive
first line therapy in all HHT patients with troublesome
epistaxis because the risk to the patient is minimal.
Level of Evidence: Level 4 (1 case series) [13]; level 5
(1 case report) [14]
Medical therapy
Hormonal
Traditionally, estrogen was the primary agent used. Vase
performed the only randomized controlled trial (RCT)
in 1981 and this failed to show a statistically significant
difference between estrogen and placebo [15]. In 1982,
Harrison detailed the successful treatment of HHT with
systemic estrogen, although this was not a randomized
trial [16]. Conversely, Tamoxifen (an anti-estrogen drug
used in the treatment of breast cancer) has also been
noted to be effective in the treatment of HHT [17, 18].
Summary: The evidence for hormonal therapy in HHT
is limited. Some studies have demonstrated efficacy,
but there is the potential for systemic side effects.
Level of Evidence: Level 1b (2 RCT) [15, 18]; level 4
(1 case series) [16]; level 5 (case report) [17]
Bevacizumab
One of the exciting advances within the management of
HHT has been the discovery of the effectiveness of
Bevacizumab (Avastin) [19, 20]. Avastin is a vascular
endothelial growth factor (VEGF) inhibitor, widely used
in the treatment of metastatic colorectal cancer and macu-
lar degeneration. Its use intranasally has been recently
studied, and it has been shown to be effective in improving
both frequency and severity of epistaxis [21–25]. When
Avastin was combined with the KTP laser, it was found
to reduce the frequency and severity of epistaxis when
compared to the laser alone; 24 % of patients in the
Avastin group reported an improvement compared to
the laser alone group [22]. It can be applied topically or
injected submucosally, though it should be noted that
injection into the cartilaginous septum has been associ-
ated with perforation (although a direct effect could
not be attributed as many of these patients also under-
went some sort of other septal cautery) [21, 22].
Summary: There is recent evidence that suggests
Bevacizumab can reduce the frequency and severity of
epistaxis in HHT patients. Care should be exercised
when injecting into the cartilaginous septum so as to
decrease risk of septal perforation.
Level of Evidence: Level 1b (1 RCT) [25]; level 3b
(1 case -control study) [22]; level 4 (3 case series)
[21, 23, 24]; level 5 (2 case reports) [19, 20]
Alternative therapies
Timolol is a beta-blocker that has also been described in
the treatment of HHT. It is applied topically to the nasal
mucosa three times per day. A review of the literature
demonstrates just 2 case reports about it, and note is
made of the risk of bradycardia as a result of the medi-
cation [26, 27]. Caution therefore should be exercised
when prescribing this medication.
Summary: There is limited evidence to support the use
Timolol, with the potential for harm (bradycardia).
Level of Evidence: Level 5 (2 case reports) [26, 27]
Another potential medical therapy that may be useful
in the future is Thalidomide. It is felt that Thalidomide
induces vessel maturation, which helps reduce the fri-
ability of the vessels [28]. However, a recent case report
described a deep vein thrombosis in a patient shortly
after initiation of Thalidomide [29]. A systematic review
by Franchini concluded that Thalidomide was a potential
Fig. 3 Relative frequencies of HHT manifestations [6, 9, 10]
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option for patients with refractory epistaxis [30]. As a re-
sult of the challenges in managing anticoagulation in this
group, alternative therapies should be considered.
Summary: There is limited evidence supporting the use
Thalidomide in HHT. A recent review suggests it may
be useful in refractory cases.
Level of Evidence: Level 3a (1 systematic review of
case–control studies) [30]; level 5 (1 case report,
1 basic science study) [28, 29]
Sclerotherapy with sodium tetradecyl sulfate (STS)
was described for use in HHT in 2011 [31]. A follow-up
prospective trial recently demonstrated the efficacy of
sclerotherapy when compared to “standard therapy” (de-
fined in this study as any treatment that the patient had
previously undergone, such as packing or cautery) [32].
Sclerotherapy works via injection of STS into the vascu-
lar lesion, which theoretically leads to thickening of the
vessel wall and subsequently less bleeding. This is a
promising new treatment that can be considered in
HHT patients.
Summary: The existing studies show benefit for
sclerotherapy. Further research into this treatment
modality is warranted.
Level of Evidence: Level 1b (1 RCT) [32]; level 4
(1 case series) [31]
Tranexamic Acid (TA) is a competitive inhibitor to plas-
minogen and works as an anti-fibrinolytic. Tranexamic
Acid has recently been evaluated in two randomized clin-
ical trials. First, Geisthoff found in a randomized, placebo-
controlled trial that while hemoglobin levels did not differ
between the placebo and the TA group, self-reported epi-
staxis was improved [33]. Gaillard found in their random-
ized, placebo-controlled trial that epistaxis duration was
significantly shortened when patients were on TA as com-
pared to placebo [34]. Neither of those trials identified any
significant adverse events from the medication. TA is
another promising option for refractory epistaxis in the
HHT patient.
Summary: The existing studies show benefit for TA.
Further research is warranted.
Level of Evidence: Level 1b (2 RCTs) [33, 34]
Lastly, it has been noted that oxygen free radicals may
play a role in the development of telangiectasias in pa-
tients with HHT [35]. Based on this, de Gussem et al.
studied whether N-acetylcysteine (NAC), a free oxygen
radical scavenger, would decrease the severity of epi-
staxis [36]. They found that the severity and frequency
of daytime epistaxis was improved following treatment
with NAC. As with the other alternative therapies, fur-
ther research is warranted.
Summary: There is limited evidence to support the use
of NAC currently.
Level of Evidence: Level 4 (1 case series) [36]; level 5
(1 basic science study) [35]
Surgery/procedural
There are many different surgical approaches available
for the treatment of HHT. As with medical therapy, a
stepwise approach should be considered.
Coagulation
Multiple techniques have been used to coagulate the tel-
angiectasias that are seen. Bipolar cautery was shown to
be a useful option for treatment of epistaxis in HHT by
Ghaderi [37]. Laser photocoagulation is also a popular
option, and many different wavelengths of laser exist.
Typically, a laser with higher tissue penetration that uses
hemoglobin as a chromophore, such as the Nd:YAG
laser, is preferred over a laser with less surface penetra-
tion. One challenge with the laser is that not all lasers
can be used with flexible fibres, and therefore reaching
further posterior in the nose can be difficult. As well, the
increased thermal damage to surrounding tissue is a
concern, and is why some authors prefer to use Cobla-
tion or ultrasonic vibration devices.
In Ghaderi’s study with bipolar cautery, the laser was
also used in 22 of the 42 patients, with no increase in
perforation or synechiae [37]. A 2011 Danish study used
a 910 nm laser and found that the time spent with active
bleeding was improved 6.5 months after treatment [38].
Lastly, ultrasonic vibrations can be used for treatment of
epistaxis as mentioned previously. A 2003 study looked
at 2 patients who were treated with the Harmonic
Scalpel, an ultrasonic device [39]. This study highlighted
the lack of damage to the surrounding mucosa, but as
long-term results were not presented, further research is
warranted.
Summary: The laser and bipolar are effective surgical
treatments for epistaxis. Head to head comparison is
lacking and is required to determine which is most
effective. The data supporting use of an ultrasonic
device in HHT is currently limited.
Level of Evidence: Level 3b (1 case–control study) [37];
level 4 (1 case series) [38]; level 5 (1 case report) [39]
Coblation
One of the more recent advances in HHT, Coblation
works via radiofrequency (RF) energy and breaks down
molecular bonds at relatively low temperatures (40-70 °C)
[40]. Three studies have looked at Coblation in HHT and
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it has been shown to be a useful alternative to other
surgical treatments [40–42]. Like the Harmonic Scalpel,
the purported advantages of Coblation are the de-
creased risk of damage to surrounding, healthy mucosa
with subsequent crust formation and the lower
temperature, which theoretically leads to less deep tis-
sue thermal injury.
Summary: In the few available studies, the Coblation
device has been successful in improving epistaxis in
HHT and could be considered a viable alternative to
coagulation and laser.
Level of Evidence: Level 4 (3 case series) [40–42]
Septodermoplasty
Septodermoplasty involves removing the affected anter-
ior septal mucosa and replacing it with a full- or split-
thickness skin graft, laying it on top of the remaining
perichondrium [43]. The nasal floor mucosa and lateral
wall mucosa can also be removed as needed [43]. It has
been shown to reduce the need for multiple laser proce-
dures by up to 57 % [44].
Disadvantages of septodermoplasty include long-term
crusting, the fact that this procedure often doesn’t com-
pletely stop all epistaxis as telangiectasias can grow
through the skin graft, and donor site morbidity. Advan-
tages include that it is an effective procedure and it is
able to address large amounts of affected mucosa with
one procedure. It can also be combined with a septect-
omy in those patients who have a perforation; this
technique has led to improved quality of life and de-
creased transfusion requirements in a group of patients
with severe transfusion-dependent HHT [45].
Summary: For refractory epistaxis in HHT patients,
septodermoplasty can be considered an invasive, but
useful, treatment.
Level of Evidence: Level 4 (3 case series) [43–45]
Embolization
The evidence of embolization in HHT is scant. A 2012
study by Trojanowski found an initial success rate of 85 %,
though the rate of epistaxis recurrence was 43 % in their
follow-up group (follow-up ranged between 6–24 months)
[46]. A study in 2007 compared 10 patients who had idio-
pathic epistaxis to 12 patients with HHT. Those in the
HHT group required significantly more re-embolizations
and additional surgeries when compared to the idiopathic
group [47]. Because of the significant risks involved with
endovascular embolization, such as stroke and blindness,
endovascular embolization is usually not recommended in
this patient population.
Summary: Embolization is infrequently recommended
for the management of epistaxis in HHT and the
evidence is limited.
Level of Evidence: Level 3 (1 case–control study) [47];
level 4 (1 case series) [46]
Young’s procedure
Nasal closure, also known as the Young’s procedure, was
first described for atrophic rhinitis in 1967, and it was
first used for HHT in 1994 [48]. This procedure involves
closing the nasal vestibule, and can be done either uni-
laterally or bilaterally. A result of a bilateral Young’s pro-
cedure is anosmia. A 2012 study by Richer looked at 36
patients, all of whom were receiving regular iron or
blood transfusions at the time of surgery. This study
found that 30 of the 36 patients had complete cessation
of epistaxis following the Young’s procedure, and none
of them required transfusions for epistaxis in the follow-
up period (mean follow-up was 34 months) [48]. While
control of epistaxis is typically very good, this must be
weighed with the anosmia and changes in taste that will
be expected to occur following this surgery. A 2013 case
report highlighted a patient who had a Young’s proced-
ure and unfortunately developed epistaxis that was re-
fractory to pressure. After having her airway secured,
her oropharynx packed, and her internal maxillary
arteries embolized (bilaterally), she eventually had her
Young’s procedure reversed to enable placement of nasal
packing. This report highlights a very rare, but life-
threatening complication that can occur post Young’s
procedure; mainly that when the nose is closed, the abil-
ity to pack the nose in a standard fashion is lost [49].
Summary: Young’s procedure is effective, but it must
be weighed against the expected changes in smell and
taste as well as long-term risks to the patient. This
procedure may have a role in select cases when
employed as unilateral treatment.
Level of Evidence: Level 4 (1 case series) [48]; level 5
(1 case report) [49]
Conclusions
Epistaxis is the most frequent manifestation of HHT and
it can range from mildly irritating to life threatening. In
the past 5 years there have been significant gains in both
the medical and surgical options available to the prac-
ticing clinician for use in this frustrating condition. Clin-
ical treatment should start with conservative options,
which have a very low risk profile and the chance for
improvement in symptoms. The medical therapy with
the best supporting body of research is Bevacizumab,
Surgical therapies should be approached in a stepwise
manner, escalating as needed to treat the patient while
at the same time minimizing risk of septal perforation.
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Additional file
Additional file 1: Video 1. A telangiectasia of the inferior turbinate is
brushed with a cotton pledget with resultant epistaxis. (MOV 7840 kb)
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